Effective June 15, 2026, Cigna policy concludes there is insufficient evidence to support atrial overdrive pacing as a treatment for obstructive sleep apnea (OSA). The update distinguishes that while some cardiac pacing modalities, notably cardiac resynchronization therapy, have reduced apneic events in central sleep apnea, atrial overdrive pacing has not demonstrated consistent efficacy for OSA in systematic reviews and randomized trials. The policy cites Anastasopoulos et al. (2016), Weng et al. (2009), and ACCF/AHA/HRS guidance (Epstein et al., 2013) to justify the determination. A health equity note reiterates OSA disparities—particularly greater severity and underdiagnosis in Black men—while not linking these directly to pacing therapy.
June 15, 2026 Revision: Atrial Overdrive Pacing Conclusion
Effective 6/15/2026 Revision: Atrial Overdrive Pacing Position
This revision clarifies Cigna's evidentiary determination regarding atrial overdrive pacing for obstructive sleep apnea (OSA) and central sleep apnea. Effective June 15, 2026, the policy states there is "insufficient evidence to demonstrate the safety and efficacy of atrial overdrive pacing in the treatment of OSA." The document continues to distinguish that while certain cardiac pacing modalities (specifically cardiac resynchronization therapy) have demonstrated reductions in apneic events for central sleep apnea in some studies, atrial overdrive pacing itself is not supported as an effective treatment for OSA.
The update explicitly references systematic reviews and meta-analyses (Anastasopoulos et al., 2016; Weng et al., 2009) and integrates guideline language from professional societies (ACCF/AHA/HRS, Epstein et al., 2013) to support the conclusion that pacing has not been established as indicated for obstructive sleep apnea with persistent bradycardia despite CPAP.
Cited Evidence: Systematic Reviews and Meta-Analyses
Evidence Summary Included in the Policy
The policy cites a 2016 systematic review (Anastasopoulos et al.) of 22 studies that differentiated effects of cardiac pacing modalities on sleep-related breathing disorders. That review concluded cardiac resynchronization therapy (CRT), not atrial overdrive pacing, reduced apneic events in central sleep apnea; the effect on OSA remained controversial and pacing could not be used alone as a treatment for sleep-related breathing disorders.
A 2009 meta-analysis (Weng et al.) of eight randomized controlled trials (n=129) is also summarized. Results suggested atrial overdrive pacing reduced AHI and increased minimum arterial oxygen saturation (SaO2) in trials where central sleep apnea predominated, but findings were unclear or not statistically significant in OSA-predominant trials. The policy frames these results as insufficient to establish efficacy of atrial overdrive pacing for OSA.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.